ATE537151T1 - Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten - Google Patents
Pyrazolinverbindungen als mineralocorticoidrezeptorantagonistenInfo
- Publication number
- ATE537151T1 ATE537151T1 AT07825488T AT07825488T ATE537151T1 AT E537151 T1 ATE537151 T1 AT E537151T1 AT 07825488 T AT07825488 T AT 07825488T AT 07825488 T AT07825488 T AT 07825488T AT E537151 T1 ATE537151 T1 AT E537151T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- mineralocorticoid receptor
- pyrazoline compounds
- pyrazoline
- compounds
- Prior art date
Links
- 229940083712 aldosterone antagonist Drugs 0.000 title 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 title 1
- 150000003219 pyrazolines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86360606P | 2006-10-31 | 2006-10-31 | |
| PCT/IB2007/003207 WO2008053300A1 (en) | 2006-10-31 | 2007-10-17 | Pyrazoline compounds as mineralocorticoid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537151T1 true ATE537151T1 (de) | 2011-12-15 |
Family
ID=39027523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07825488T ATE537151T1 (de) | 2006-10-31 | 2007-10-17 | Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US7781428B2 (de) |
| EP (1) | EP2089367B1 (de) |
| JP (1) | JP4977760B2 (de) |
| KR (1) | KR101107800B1 (de) |
| CN (1) | CN101541757A (de) |
| AP (1) | AP2527A (de) |
| AR (1) | AR063529A1 (de) |
| AT (1) | ATE537151T1 (de) |
| AU (1) | AU2007315884B2 (de) |
| BR (1) | BRPI0717937A2 (de) |
| CA (1) | CA2667966C (de) |
| CL (1) | CL2007003154A1 (de) |
| CO (1) | CO6160307A2 (de) |
| CR (1) | CR10725A (de) |
| CU (1) | CU23779B7 (de) |
| CY (1) | CY1112311T1 (de) |
| DK (1) | DK2089367T3 (de) |
| EA (1) | EA016370B1 (de) |
| ES (1) | ES2375877T3 (de) |
| GE (1) | GEP20115239B (de) |
| GT (1) | GT200700096A (de) |
| HN (1) | HN2007000437A (de) |
| HR (1) | HRP20120078T1 (de) |
| IL (1) | IL198241A0 (de) |
| MA (1) | MA30821B1 (de) |
| MX (1) | MX2009004662A (de) |
| MY (1) | MY145795A (de) |
| NI (1) | NI200900071A (de) |
| NO (1) | NO20091741L (de) |
| NZ (1) | NZ575923A (de) |
| PE (1) | PE20081472A1 (de) |
| PL (1) | PL2089367T3 (de) |
| PT (1) | PT2089367E (de) |
| RS (2) | RS52203B (de) |
| SI (1) | SI2089367T1 (de) |
| TN (1) | TN2009000160A1 (de) |
| TW (1) | TWI357327B (de) |
| UA (1) | UA92670C2 (de) |
| UY (1) | UY30670A1 (de) |
| WO (1) | WO2008053300A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| MX336881B (es) * | 2009-10-29 | 2016-02-04 | Bristol Myers Squibb Co | Compuestos heterociclicos triciclicos. |
| JP6148175B2 (ja) | 2010-05-10 | 2017-06-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 網膜中および／または網膜下における液体貯留の処置のための方法および組成物 |
| JP2013528598A (ja) | 2010-05-11 | 2013-07-11 | ファイザー・インク | ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物 |
| EP2582365B1 (de) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Zusammensetzungen zur stimulierung der reepithelialisation während der wundheilung |
| CN102372710A (zh) * | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
| WO2012048022A2 (en) * | 2010-10-05 | 2012-04-12 | Nova Southeastern University | Methods and compositions for therapeutic modulation of aldosterone levels in heart disease |
| PT3160948T (pt) | 2014-06-30 | 2019-02-01 | Astrazeneca Ab | Amidas benzoxazinona como moduladores de recetor de mineralocorticoide |
| ES2846835T3 (es) | 2015-10-13 | 2021-07-29 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea |
| ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
| EP3507278B1 (de) | 2016-09-02 | 2021-01-27 | Bristol-Myers Squibb Company | Substituierte tricyclische heterocyclische verbindungen |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| WO2019032631A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | Oxime ether compounds |
| US20230151425A1 (en) | 2020-03-11 | 2023-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| EP4395785A1 (de) | 2021-08-31 | 2024-07-10 | Inserm (Institut National de la Santé et de la Recherche Scientifique) | Verfahren zur behandlung von augenrosacea |
| CN113679716B (zh) | 2021-10-13 | 2024-03-26 | 史大永 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
| CN114230457B (zh) * | 2022-01-04 | 2023-06-09 | 中山大学 | 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1086068A (en) | 1964-09-02 | 1967-10-04 | Ici Ltd | Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein |
| BE789948A (fr) | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
| US3816438A (en) | 1972-12-22 | 1974-06-11 | Sandoz Ag | 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles |
| US3843666A (en) | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
| US4866025A (en) | 1988-09-30 | 1989-09-12 | Eastman Kodak Company | Thermally-transferable fluorescent diphenylpyrazolines |
| ES2098547T3 (es) | 1992-01-23 | 1997-05-01 | Pfizer | Benzopirano y otros antagonistas de ltb4 relacionados. |
| GB9318691D0 (en) | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| ID16283A (id) | 1996-03-20 | 1997-09-18 | Astra Pharma Prod | Senyawa yang berguna dibidang farmasi |
| CA2263586A1 (en) * | 1996-09-05 | 1998-03-12 | Eifion Phillips | Novel aryl-pyridazines |
| JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| IT1292092B1 (it) | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
| CN1311678A (zh) | 1998-04-30 | 2001-09-05 | 巴斯福股份公司 | 具有蛋白激酶活性的取代的三环吡唑衍生物 |
| US6432974B1 (en) | 2000-02-04 | 2002-08-13 | Wyeth | Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor |
| JP4399269B2 (ja) | 2002-03-08 | 2010-01-13 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害薬 |
| WO2003078394A1 (en) | 2002-03-15 | 2003-09-25 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| JP4733388B2 (ja) | 2002-08-02 | 2011-07-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
| KR20050044807A (ko) | 2002-09-18 | 2005-05-12 | 화이자 프로덕츠 인코포레이티드 | 전환 성장 인자 억제제로서의 피라졸 유도체 |
| US20060235222A1 (en) | 2003-01-22 | 2006-10-19 | Eli Lilly And Company | Indole-derivative modulators of steroid hormone nuclear receptors |
| CN1918151A (zh) | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
| JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
| WO2006010142A2 (en) | 2004-07-14 | 2006-01-26 | Ligand Pharmaceuticals, Inc. | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use |
| WO2006012642A2 (en) | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
| US20110144128A1 (en) | 2005-01-10 | 2011-06-16 | Exelixis, Inc. | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands |
| JPWO2006077821A1 (ja) | 2005-01-19 | 2008-06-19 | 大日本住友製薬株式会社 | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
| CN101115745A (zh) | 2005-02-10 | 2008-01-30 | 默克公司 | 有丝分裂驱动蛋白抑制剂 |
-
2007
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2007-10-17 EP EP07825488A patent/EP2089367B1/de active Active
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 RS RS20120051A patent/RS52203B/sr unknown
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en not_active Ceased
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active Expired - Fee Related
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
-
2009
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
-
2012
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE537151T1 (de) | Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten | |
| ATE481405T1 (de) | Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors | |
| EP1981902A4 (de) | Nogo-rezeptorantagonisten | |
| DK2089382T3 (da) | Substituerede diazepan-forbindelser som orexin-receptor-antagonister | |
| EP2150115A4 (de) | Cyclopropylpyrrolidinorexin-rezeptorantagonisten | |
| ATE540942T1 (de) | Imidazolderivate als ccr2-rezeptor-antagonisten | |
| DK2081951T3 (da) | Progesteron-receptorantagonister | |
| DK2009992T3 (da) | Il-8 receptor-antagonister | |
| ATE509022T1 (de) | Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide | |
| ATE555111T1 (de) | Chinuclidinol-derivate als muscarinrezeptor- antagonisten | |
| BRPI0910592A2 (pt) | antagonistas de receptor 2 de somatostatina | |
| DK2252581T3 (da) | Kappa-selektiv opioidreceptorantagonist | |
| ATE509928T1 (de) | 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten | |
| EP2079466A4 (de) | Substituierte indolverbindungen | |
| ATE395335T1 (de) | Als muscarinrezeptorantagonisten geeignete biphenylverbindungen | |
| ATE538091T1 (de) | Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren | |
| ATE519738T1 (de) | Pyrrolidinarylether als nk3-rezeptorantagonisten | |
| ATE517100T1 (de) | Pyrrolidinarylether als nk3-rezeptorantagonisten | |
| ATE545633T1 (de) | Als vasopressinantagonisten geeignete benzazepinderivate | |
| EP2350304A4 (de) | Antagonisten des toll-ähnlichen rezeptors 3 | |
| ATE485270T1 (de) | 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors | |
| ATE477243T1 (de) | 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten | |
| HRP20160950T1 (hr) | Polimorfi antagonista mglur5 receptora | |
| ATE421511T1 (de) | Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors | |
| ATE547407T1 (de) | Alkylthiopyrimidine als crth2-antagonisten |